Exploring the disconnect: mechanisms underpinning the absence of physical function improvement with SGLT2 inhibitors

Current evidence suggests sodium-glucose cotransporter 2 inhibitors (SGLT2i) do not consistently improve patient physical function, despite improvements in clinical symptoms and reductions in both adiposity and body weight. We highlight heterogenous methodologies in SGLT2i physical function trials....

Descripció completa

Dades bibliogràfiques

Autors principals:	Cian Sutcliffe, Jack A. Sargeant, Thomas Yates, Melanie J. Davies, Luke A. Baker
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2025-05-01
Col·lecció:	Frontiers in Systems Biology
Matèries:	SGLT2 (sodium-glucose cotransporter 2) inhibitor Glucagon-like peptide 1 (GLP-1) receptor agonist physical function skeletal muscle glucose lowering medication mobility and ageing
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fsysb.2025.1593229/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!